Tia Bush Sells 40,000 Shares of Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) CTO Tia Bush sold 40,000 shares of the stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $26.00, for a total transaction of $1,040,000.00. Following the sale, the chief technology officer owned 121,503 shares of the company’s stock, valued at approximately $3,159,078. This trade represents a 24.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $27.61 on Friday. The company has a quick ratio of 10.57, a current ratio of 10.56 and a debt-to-equity ratio of 0.36. The firm has a market cap of $3.70 billion, a price-to-earnings ratio of -15.09 and a beta of 1.56. The company’s fifty day simple moving average is $23.17 and its 200 day simple moving average is $17.50. Centessa Pharmaceuticals PLC Sponsored ADR has a 12-month low of $9.60 and a 12-month high of $27.72.

Centessa Pharmaceuticals (NASDAQ:CNTA) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). On average, analysts expect that Centessa Pharmaceuticals PLC Sponsored ADR will post -1.6 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Avoro Capital Advisors LLC boosted its stake in shares of Centessa Pharmaceuticals by 116.2% in the 3rd quarter. Avoro Capital Advisors LLC now owns 10,808,080 shares of the company’s stock worth $262,096,000 after buying an additional 5,808,080 shares during the last quarter. Adage Capital Partners GP L.L.C. lifted its holdings in Centessa Pharmaceuticals by 20.8% during the second quarter. Adage Capital Partners GP L.L.C. now owns 8,403,000 shares of the company’s stock worth $110,415,000 after acquiring an additional 1,449,000 shares during the period. Commodore Capital LP boosted its position in Centessa Pharmaceuticals by 39.3% in the second quarter. Commodore Capital LP now owns 3,298,289 shares of the company’s stock worth $43,340,000 after purchasing an additional 930,711 shares during the last quarter. Franklin Resources Inc. boosted its position in Centessa Pharmaceuticals by 0.6% in the third quarter. Franklin Resources Inc. now owns 2,558,414 shares of the company’s stock worth $62,042,000 after purchasing an additional 14,875 shares during the last quarter. Finally, Federated Hermes Inc. bought a new position in Centessa Pharmaceuticals in the 3rd quarter valued at $42,429,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on CNTA shares. Oppenheimer initiated coverage on Centessa Pharmaceuticals in a report on Friday, August 29th. They issued an “outperform” rating and a $40.00 target price for the company. Wells Fargo & Company increased their target price on shares of Centessa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “overweight” rating in a research note on Thursday. Guggenheim restated a “buy” rating and issued a $28.00 price target on shares of Centessa Pharmaceuticals in a report on Monday, October 6th. Wall Street Zen raised shares of Centessa Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $33.11.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.